Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manmath Patekar

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Dermatologic Therapy|December 26, 2021
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trialBardur Sigurgeirsson, John Browning, Stephen Tyring, et al.
American Journal of Clinical Dermatology|June 21, 2023
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical TrialsMichael Sticherling, Arjen F Nikkels, Ashraf M Hamza, et al.
JAMA Dermatology|October 1, 2020
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing SpondylitisBoni E Elewski, John W Baddley, Atul A Deodhar, et al.
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
Allergy|December 8, 2025
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous UrticariaAna M Gimenez-Arnau, Marcus Maurer, Adam Reich, et al.
The New England Journal of Medicine|June 3, 2026
Phase 3 Trial of Secukinumab in Polymyalgia RheumaticaJohn H Stone, Frank Buttgereit, Alain Saraux, et al.
Chinese Medical Journal|October 16, 2020
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasisLin Cai, Jian-Zhong Zhang, Xu Yao, et al.
Lancet (London, England)|November 26, 2023
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trialsMarcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Dermatologic Therapy|December 26, 2021
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trialBardur Sigurgeirsson, John Browning, Stephen Tyring, et al.
American Journal of Clinical Dermatology|June 21, 2023
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical TrialsMichael Sticherling, Arjen F Nikkels, Ashraf M Hamza, et al.
JAMA Dermatology|October 1, 2020
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing SpondylitisBoni E Elewski, John W Baddley, Atul A Deodhar, et al.
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
Allergy|December 8, 2025
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous UrticariaAna M Gimenez-Arnau, Marcus Maurer, Adam Reich, et al.
The New England Journal of Medicine|June 3, 2026
Phase 3 Trial of Secukinumab in Polymyalgia RheumaticaJohn H Stone, Frank Buttgereit, Alain Saraux, et al.
Chinese Medical Journal|October 16, 2020
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasisLin Cai, Jian-Zhong Zhang, Xu Yao, et al.
Lancet (London, England)|November 26, 2023
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trialsMarcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, et al.
Pageof 2